Genetic Regulation of Skeletal Muscle Protein Turnover During Prolonged Immobilization

Abstract

Prolonged immobilization produces rapid skeletal muscle wasting, reduced force generation, impaired metabolic flexibility, and delayed functional recovery. Although disuse atrophy has traditionally been described as an imbalance between protein synthesis and degradation, contemporary research demonstrates that this response is governed by coordinated genetic, epigenetic, transcriptional, translational, and post-translational mechanisms. Reduced mechanical loading suppresses anabolic signaling through the insulin-like growth factor 1–AKT–mechanistic target of rapamycin pathway, while activating forkhead box O transcription factors, the ubiquitin–proteasome system, autophagy–lysosomal degradation, and myostatin-related inhibitory networks. Mitochondrial dysfunction, inflammation, oxidative stress, denervation-like signaling, and altered microRNA expression further influence muscle protein turnover. These mechanisms have direct clinical relevance in intensive care, orthopedics, neurology, geriatrics, and rehabilitation medicine. Diagnosis should integrate functional assessment, nutritional evaluation, and, when appropriate, biochemical or imaging-based characterization. Management requires early mobilization, progressive resistance exercise, adequate protein and energy provision, treatment of systemic illness, and individualized rehabilitation. Emerging strategies include selective modulation of myostatin and activin signaling, anabolic pharmacology, neuromuscular electrical stimulation, and precision approaches based on genomic and epigenomic profiles. A mechanistic understanding of genetic regulation may improve risk stratification and support targeted interventions that preserve muscle quality during unavoidable periods of immobilization.

Introduction

Skeletal muscle is a highly adaptable tissue whose mass and performance depend on the dynamic balance between protein synthesis, protein degradation, contractile activity, neural input, endocrine signaling, and nutritional availability. Immobilization disrupts this balance within days. Bed rest, limb casting, mechanical ventilation, postoperative restriction, spinal cord injury, and severe systemic disease can all reduce mechanical loading and accelerate loss of muscle mass. The decline is not limited to muscle size; it also affects fiber composition, insulin sensitivity, mitochondrial capacity, tendon interaction, and neuromuscular coordination.

Genetic regulation is central to this process. Mechanical unloading changes the expression of genes involved in myofibrillar maintenance, amino acid transport, autophagy, ubiquitin conjugation, mitochondrial biogenesis, extracellular matrix remodeling, and inflammatory signaling. These gene-expression programs are shaped by transcription factors, chromatin accessibility, DNA methylation, histone modification, and noncoding RNAs. Understanding these pathways is important for clinicians because the speed and severity of atrophy vary considerably among patients exposed to apparently similar periods of immobilization.

Epidemiology / Disease Burden

Muscle wasting during immobilization is common across acute and chronic healthcare settings. Hospitalized older adults may lose substantial lower-limb strength during a short admission, while patients in intensive care can develop profound weakness associated with prolonged ventilation, systemic inflammation, corticosteroid exposure, and neuromuscular dysfunction. Patients with hip fracture, stroke, spinal cord injury, orthopedic trauma, and prolonged postoperative restrictions are particularly vulnerable. The burden extends beyond reduced muscle circumference: weakness increases falls, pressure injury, venous thromboembolism, dependence in activities of daily living, institutionalization, and mortality.

Disuse-related atrophy also contributes to longer rehabilitation requirements and higher healthcare utilization. The loss of strength is often greater than the reduction in muscle mass because immobilization affects excitation–contraction coupling, motor-unit recruitment, fiber quality, and connective tissue function. Older adults, individuals with sarcopenia, and patients with diabetes or chronic inflammatory disease have reduced physiological reserve and may experience disproportionate functional decline.

Pathophysiology

Mechanical unloading reduces integrin and focal adhesion signaling, cytoskeletal tension, and downstream activation of phosphatidylinositol 3-kinase, AKT, and mechanistic target of rapamycin complex 1. As a result, translation initiation and ribosomal activity decline, limiting synthesis of myosin, actin, and other contractile proteins. Reduced insulin or insulin-like growth factor signaling may further impair AKT activity. In parallel, dephosphorylated forkhead box O transcription factors enter the nucleus and induce genes such as atrogin-1 and muscle RING-finger protein 1, which encode E3 ubiquitin ligases involved in selective proteolysis.

The ubiquitin–proteasome system targets damaged and regulatory proteins for degradation, whereas autophagy–lysosomal pathways remove protein aggregates and dysfunctional organelles. These systems are necessary for cellular quality control but become maladaptive when persistently activated. Myostatin and activin A signaling through activin type II receptors and SMAD transcription factors suppresses muscle growth and may promote catabolic gene expression. Calcium imbalance, reactive oxygen species, mitochondrial fragmentation, and impaired oxidative phosphorylation amplify proteolytic signaling. In critically ill patients, inflammatory mediators such as tumor necrosis factor and interleukin-6 may activate nuclear factor kappa B and other pathways that accelerate loss of muscle protein.

Epigenetic mechanisms provide an important link between mechanical loading and durable changes in gene expression. Altered DNA methylation, histone acetylation, and chromatin remodeling can persist after the initial immobilization period and may contribute to incomplete recovery. MicroRNAs, including muscle-enriched regulatory species, influence translation of transcripts involved in hypertrophy, fibrosis, metabolism, and regeneration. Long noncoding RNAs and circular RNAs are also being investigated as regulators of muscle adaptation. Satellite cells may show impaired activation during prolonged disuse, limiting repair and regeneration after remobilization.

Risk Factors

Important risk factors include duration and severity of unloading, complete limb immobilization, prolonged bed rest, mechanical ventilation, sepsis, multiorgan failure, denervation, advanced age, malnutrition, inadequate protein intake, vitamin D deficiency, diabetes, chronic kidney disease, malignancy, and systemic corticosteroid therapy. Pre-existing sarcopenia, frailty, obesity with low muscle quality, and peripheral neuropathy increase vulnerability. Sedative exposure, deep sedation, pain, delirium, restrictive devices, and delayed physiotherapy can prolong immobility. Genetic variation in pathways regulating anabolic signaling, inflammation, proteolysis, and muscle regeneration may also contribute to interindividual differences, although routine genetic testing is not currently recommended.

Clinical Features

Clinical manifestations include symmetrical weakness, reduced endurance, difficulty standing or transferring, impaired gait, loss of stair-climbing ability, and reduced respiratory muscle performance. Patients may report fatigue and exercise intolerance rather than obvious muscle wasting, particularly early in the course. Intensive care patients can develop difficulty weaning from mechanical ventilation because of diaphragmatic and peripheral muscle weakness. Contractures, joint stiffness, balance impairment, neuropathic symptoms, and pressure injuries may coexist. The clinical pattern should be interpreted in relation to the original illness because weakness may reflect critical illness polyneuropathy, myopathy, medication effects, central nervous system disease, or a combination of these conditions.

Diagnosis

Assessment begins with a detailed history of immobilization, nutritional intake, premorbid function, comorbidities, medication exposure, and neurological symptoms. Serial measurement of grip strength, the Medical Research Council sum score, sit-to-stand performance, gait speed, and standardized functional scales can document progression and recovery. In intensive care, validated approaches to critical illness weakness should be used when the patient is sufficiently alert and cooperative.

Ultrasound can estimate changes in muscle thickness and architecture at the bedside, while bioimpedance, dual-energy X-ray absorptiometry, and computed tomography may provide broader assessments of lean mass and muscle quality when clinically indicated. Laboratory tests should be directed toward reversible contributors and may include blood counts, renal and hepatic profiles, thyroid studies, vitamin D assessment, inflammatory markers, and creatine kinase when alternative myopathic processes are suspected. Electrophysiological testing is useful when denervation, neuropathy, or primary myopathy remains a concern. Muscle biopsy and molecular studies are generally reserved for research or diagnostically complex cases.

Treatment & Management

Management should begin as soon as medically safe. Early mobilization, active range-of-motion exercises, progressive resistance training, and task-specific rehabilitation counteract unloading-induced suppression of anabolic signaling. Neuromuscular electrical stimulation may be useful when voluntary contraction is limited, although protocols should be individualized according to skin integrity, implanted devices, pain, and neuromuscular status. Respiratory muscle training can support ventilator liberation and improve functional recovery in selected patients.

Nutritional therapy should provide sufficient energy and high-quality protein while accounting for renal, hepatic, and metabolic conditions. Protein distribution across meals, adequate essential amino acids, and attention to leucine-rich sources may support muscle protein synthesis, but supplementation should not replace rehabilitation or treatment of the underlying illness. Vitamin D deficiency and other clinically significant deficiencies should be corrected. Clinicians should minimize unnecessary sedation, review corticosteroid exposure, prevent delirium, control pain, and coordinate physiotherapy with nursing, nutrition, and medical teams. Resistance exercise after remobilization is essential because recovery of strength often lags behind restoration of muscle volume.

Recent Advances / Emerging Therapies

Therapeutic research is increasingly focused on pathway-specific interventions. Inhibitors of myostatin or activin receptor signaling have demonstrated anabolic potential in selected muscle-wasting disorders, although durability, functional benefit, cardiovascular safety, and appropriate patient selection remain under evaluation. Agents that influence androgen signaling, selective androgen receptor modulation, or growth factor pathways have also been investigated, but adverse effects and uncertain long-term outcomes limit routine use for immobilization-associated atrophy.

Research into microRNA-based therapeutics, epigenetic modifiers, mitochondrial enhancers, anti-inflammatory strategies, and autophagy regulation may eventually permit more precise treatment. Omics technologies are being used to identify molecular signatures associated with rapid wasting or poor recovery. These approaches could support precision rehabilitation by integrating genotype, baseline muscle phenotype, inflammatory status, medication exposure, and response to exercise. However, most candidates remain investigational, and treatment should currently prioritize established rehabilitation, nutritional, and supportive-care measures.

Guideline Recommendations

Clinical guidance from critical care, geriatric, rehabilitation, and nutrition organizations consistently supports early assessment of mobility and nutritional risk, prevention of avoidable immobility, and progressive rehabilitation as tolerated. Mobilization should be coordinated with hemodynamic, respiratory, neurological, and orthopedic safety criteria. Protein and energy prescriptions should be individualized rather than based solely on body weight, particularly in obesity, renal impairment, or critical illness. Functional outcomes, not muscle mass alone, should guide treatment decisions. Regular reassessment is required because exercise tolerance, consciousness, organ function, and nutritional needs change rapidly during recovery.

Genetic or molecular testing should not be used routinely to diagnose disuse atrophy or select unproven biologic therapies. Clinicians should distinguish immobilization-related wasting from inflammatory myopathy, endocrine disease, motor neuron disease, medication-induced myopathy, and critical illness polyneuropathy. Shared decision-making is important when considering investigational interventions, and therapies with uncertain functional benefit should be used only within appropriate clinical research or specialist frameworks.

Conclusion

Prolonged immobilization triggers a genetically regulated shift from muscle protein synthesis toward proteolysis, impaired regeneration, mitochondrial dysfunction, and reduced neuromuscular performance. The interaction of mechanical unloading, anabolic resistance, forkhead box O activation, ubiquitin–proteasome signaling, autophagy, myostatin pathways, inflammation, and epigenetic remodeling explains the rapid and heterogeneous nature of muscle loss. Early mobilization, progressive resistance exercise, adequate nutrition, treatment of systemic disease, and coordinated multidisciplinary rehabilitation remain the foundation of care. Emerging molecular therapies may eventually enable risk-adapted prevention and precision treatment, but their clinical role requires further evidence demonstrating sustained functional benefit and acceptable safety.